BOSTON--(BUSINESS WIRE)--Columbia Laboratories, Inc. (NasdaqCM:CBRX) received notice on August 23, 2012, from the Nasdaq Stock Market that the Company has regained compliance with the Nasdaq Stock Market minimum bid price requirement as set forth in Listing Rule 5550(a)(2). The notice stated that the closing bid price of the Company's common stock has been at $1.00 per share or greater for the previous ten consecutive business days.
About Columbia Laboratories
Columbia Laboratories, Inc. is a publicly traded specialty pharmaceutical company with a successful history of developing proprietary, vaginally administered products for women’s health indications. For more information, please visit www.columbialabs.com.